Insellar is developing a minimally invasive brain interface for treatment-resistant depression and related psychiatric conditions. The company is based in Berlin and frames its approach around physiological neuromodulation, with a focus on engaging endogenous hormone-release pathways involved in mood, bonding, stress, and emotional regulation.

Its concept focuses on stimulating inner-brain or neuroendocrine structures to trigger the release of protective hormones, including oxytocin. Public materials describe a patented brain-computer interface and an early device program, although detailed system architecture remains limited in public sources.

Insellar is using pre-seed funding to build and validate a functional prototype, establish preclinical proof of concept, and prepare for clinical development in Europe and the United States. The company is best understood as a preclinical psychiatric neuromodulation startup applying bioelectronic medicine logic to severe depression.